Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices and global specialty drug logistics (World Courier). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Last trade$351.71
Day change-$5.23 (-1.47%)
Day range$351.19 – $360.36
Volume571,755
Market cap$68.11B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$68.11B
Price / earnings
25.95×
Price / book
22.33×
Price / sales
0.2×
EV / sales
0.23×
EV / EBITDA
13.76×
Profitability
Earnings per share
$13.75
Return on assets
3.13%
Return on equity
86.03%
Dividend yield
0.69%
Liquidity and leverage
Debt / equity
3.84×
Current ratio
0.95×
Quick ratio
0.59×
Cash ratio
0.05×
Cash flow
Price / cash flow
14.13×
Price / free cash flow
16.78×
Free cash flow
$4.06B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for COR, quarterly periods
Line item
Q3 FY2026 Jun 30, 2026
Q2 FY2026 Mar 31, 2026
Q1 FY2026 Dec 31, 2025
Q4 FY2025 Sep 30, 2025
Q3 FY2025 Jun 30, 2025
Q2 FY2025 Mar 31, 2025
Q1 FY2025 Dec 31, 2024
Q4 FY2024 Sep 30, 2024
Revenue
$84.75B
$78.36B
$85.93B
$83.73B
$80.66B
$75.45B
$81.49B
$79.05B
Cost of revenue
$81.15B
$74.77B
$82.86B
$80.77B
$77.76B
$72.39B
$78.93B
$76.56B
Gross profit
$3.61B
$3.59B
$3.07B
$2.95B
$2.91B
$3.06B
$2.56B
$2.49B
Selling, general and administrative
$2.13B
$1.98B
$1.8B
$1.75B
$1.67B
$1.6B
$1.47B
$1.49B
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$2.49B
$2.45B
$2.31B
$2.94B
$2.04B
$2.02B
$1.85B
$2.37B
Operating income
$1.12B
$1.14B
$760.45M
$18.5M
$867.65M
$1.04B
$706.25M
$126.64M
Interest expense
-$140.71M
-$140.46M
-$72.41M
-$77.83M
-$81.79M
-$103.99M
-$27.93M
-$20.97M
Income before taxes
$996.39M
$2.09B
$708.64M
-$187.04M
$896.28M
$928.66M
$620.45M
$125.18M
Income taxes
$219.73M
$459.04M
$142.51M
$146.03M
$206.53M
$211.24M
$126.73M
$117.71M
Net income
$776.67M
$1.63B
$566.13M
-$333.07M
$689.75M
$717.42M
$493.72M
$7.47M
Net income attributable to common shareholders
$763.52M
$1.64B
$559.65M
-$339.7M
$687.4M
$717.87M
$488.6M
$3.38M
EBITDA
$1.48B
$1.62B
$1.28B
$1.21B
$1.24B
$1.46B
$1.09B
$1B
Basic earnings per share
$3.95
$8.44
$2.88
-$1.75
$3.55
$3.70
$2.52
$0.02
Diluted earnings per share
$3.94
$8.40
$2.87
-$1.74
$3.52
$3.68
$2.50
$0.02
Recent news
Company coverage with links to the original publishers.
Following a significant market crash where the Nasdaq dropped 5.5% and $2.3 trillion in market value was wiped out due to tech stock selloffs and AI concerns, three companies recently announced dividend increases: Becton Dickinson ($1.06/share, 8th hike in 5 years), Cencora ($0.66/share, 6th hike in 5 years), and UniFirst ($0.38/share, 6th hike in 5 years). These dividend-paying stocks are highlighted as potential defensive investments for conservative investors seeking steady income during market turbulence.
Cencora reported Q4 fiscal 2026 adjusted EPS of $4.66, beating estimates by 2.2%, with revenues rising 5.5% to $88.35B. Growth was driven by specialty pharmaceutical volumes, GLP-1 drug demand, and the OneOncology acquisition. The company projects fiscal 2027 EPS of $19.40-$19.75 (8-10% growth), announced a specialty-focused organizational restructure, and raised its quarterly dividend by 10%.
Cencora reported Q3 2026 earnings of $4.66 per share, beating consensus estimates of $4.56, with revenues of $88.35 billion slightly exceeding expectations. The company has outperformed consensus EPS estimates three times over the last four quarters. Despite underperforming the S&P 500 year-to-date, Cencora received a Zacks Rank #2 (Buy) rating with favorable estimate revision trends. The Medical Services industry ranks in the top 45% of Zacks industries.
Cencora (COR), a major pharmaceutical distribution and healthcare solutions provider, has been highlighted as a stock to watch with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company is forecasted to achieve 11.8% year-over-year earnings growth for the current fiscal year, with two analysts revising earnings estimates upward in the last 60 days.
Mettler-Toledo is set to report Q3 2026 results on Nov. 5, with revenues estimated to grow 3.9% to $1.07 billion and EPS projected to increase 8.6% to $12.11. The company is expected to benefit from improving market conditions in China and emerging markets, strong demand for automation solutions, and contributions from recent acquisitions and the Spinnaker sales program.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Nov 13, 2026
$0.66
Nov 30, 2026
recurring
Aug 14, 2026
$0.60
Aug 31, 2026
recurring
May 15, 2026
$0.60
Jun 1, 2026
recurring
Feb 13, 2026
$0.60
Mar 2, 2026
recurring
Nov 14, 2025
$0.60
Dec 1, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.